A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Clinical trial NCT06644768 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06644768
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-30
- Primary completion
- 2028-03-30
- Enrollment
- 137
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.